The lancet oncology
-
The lancet oncology · Jul 2017
Randomized Controlled Trial Multicenter Study Comparative StudyCT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
CT-P6 is a proposed biosimilar to reference trastuzumab. In this study, we aimed to establish equivalence of CT-P6 to reference trastuzumab in neoadjuvant treatment of HER2-positive early-stage breast cancer. ⋯ Celltrion Inc.